Endoscopic Retrograde Appendicitis Therapy Changing Outlook For Appendicitis Treatment Compared To Laparoscopy.
- byDoctor News Daily Team
- 05 July, 2025
- 0 Comments
- 0 Mins
Endoscopic retrograde appendicitis therapy (ERAT) was found to be technically feasible and changed the treatment perspective of uncomplicated acute appendicitis when compared to laparoscopic surgery as per a study published in the journal, "Endoscopy."
ERAT is a novel and minimally invasive technique for the treatment of acute appendicitis. So, researchers from China conducted a study to assess the efficacy and clinical outcomes of ERAT versus laparoscopic appendectomy for patients with uncomplicated acute appendicitis. The study was carried out between April 2017 and March 2020. Using propensity score matching, out of 2880 suspected acute appendicitis patients, 422 patients with uncomplicated acute appendicitis who met the matching criteria were included with 79 in ERAT and 343 in Laparoscopic appendectomy thus yielding 78 pairs of patients.
Results:
ERAT had a 92.1% of curative treatment rate within 1 year.
94.7% of patients recorded a visual analog scale of ≤ 3 for pain at 6 hours after treatment in the ERAT group which was significantly higher than that in the laparoscopic appendectomy group.
Median procedure time and median hospital length of stay were significantly lower in the ERAT group compared with the laparoscopic appendectomy group.
The median recurrence time was 50 days in the ERAT group at 1 year.
The overall adverse event rate was 18.4 % in the ERAT group and 24.4 % in the laparoscopic appendectomy group.
Take home points:
This non-inferiority retrospective study compared the clinical outcomes of endoscopic retrograde appendicitis therapy (ERAT) with those of standard laparoscopic appendectomy (LA) for uncomplicated acute appendicitis in 422 patients (79 underwent ERAT and 343 underwent LA).
Overall, 97.4% of the patients underwent successful appendiceal intubation and 92.1% of the patients did not require surgery within 1 year of ERAT compared with 100% for LA.
At a 11% non-inferiority margin, ERAT was non-inferior to LA.
Overall, 63.2% of the patients undergoing ERAT underwent saline flushing into the appendiceal lumen, whereas the other 36.8% also had a stent placed.
Among patients who underwent saline flushing alone, 7.9% redeveloped appendicitis with a median recurrence time of 50 days.
There were no significant differences in short-term adverse event rates between the two therapies and only 1 patient undergoing ERAT developed an appendiceal perforation (1.3%).
The patients who underwent ERAT reported a significantly lower degree of abdominal pain and had lower hospitalization durations than patients who underwent LA.
ERAT appears to be a promising therapy for uncomplicated acute appendicitis. However, a randomized controlled study with larger sample size is needed to further evaluate this treatment modality.
To read the full article, click here: 10.1055/a-1759-2859
Podda M. Endoscopic retrograde appendicitis therapy: a starting point for a change of perspective in treating acute appendicitis (and beyond). Endoscopy. 2022;54(8):755-756.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Pfizer files lawsuit against Metsera, its Director...
- 02 November, 2025
Health Ministry achieves 3 Guinness World Records...
- 02 November, 2025
Roche gets CE mark for Elecsys Dengue Ag test to d...
- 02 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!